MannKind Corp. (MNKD)

[Denise Chanterelle]

It's inevitable to those who are invested here, the profoundly positive impact Afrezza will have in the world of diabetes therapies. Once Afrezza's absorption kinetics are understood by healthcare providers and patients, Afrezza will become the new “normal science” for treating diabetes. Afrezza will overtake basal insulin as the first course of insulin therapy for type 2 diabetics going onto insulin therapy (earlier in the treatment plan) and will replace existing RAA options for a majority of patients already on prandial insulin. When this happens, not only will Afrezza reach “mega-blockbuster” status but it could become the most valuable drug of our time. The Paradigm Shift of Afrezza is inevitable -- improving the health and Quality of Life for millions of diabetics. Help is coming soon to all who are suffering from this horrible disease!! Aloha.